Change in hemoglobin trajectory and darbepoetin dose approaching end-stage renal disease: Data from the trial to reduce cardiovascular events with aranesp therapy trial

Finnian R. Mc Causland, Brian Claggett, Marc A. Pfeffer, Emmanuel A. Burdmann, Kai Uwe Eckardt, Andrew S. Levey, John J.V. McMurray, Giuseppe Remuzzi, Ajay K. Singh, Scott D. Solomon, Robert D. Toto, Patrick Parfrey